Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant mFOLFIRINOX in Borderline Resectable Pancreatic Cancer
NCT02749136Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- May 2016
- Primary completion
- Sep 2019
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil, folinic acid in pancreatic adenocarcinoma (PDAC), sponsored by Asan Medical Center. Started May 2016; status: completed.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02749136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02749136.